Concepts (299)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Leishmaniasis, Cutaneous | 3 | 2018 | 48 | 2.10 | Why? |
| Leishmaniasis, Visceral | 6 | 2018 | 85 | 1.96 | Why? |
| Antiprotozoal Agents | 3 | 2018 | 83 | 1.49 | Why? |
| Anthelmintics | 4 | 2018 | 104 | 1.12 | Why? |
| Disease Eradication | 3 | 2018 | 581 | 0.99 | Why? |
| Onchocerciasis, Ocular | 1 | 2018 | 7 | 0.78 | Why? |
| Diarylquinolines | 2 | 2018 | 90 | 0.75 | Why? |
| Hemorrhagic Fever, Ebola | 3 | 2018 | 1475 | 0.73 | Why? |
| Neglected Diseases | 2 | 2021 | 381 | 0.68 | Why? |
| Praziquantel | 1 | 2017 | 44 | 0.68 | Why? |
| Leishmaniasis | 1 | 2017 | 26 | 0.67 | Why? |
| Breast Diseases | 1 | 2018 | 75 | 0.66 | Why? |
| Arbovirus Infections | 1 | 2018 | 104 | 0.64 | Why? |
| Schistosomiasis | 1 | 2017 | 59 | 0.62 | Why? |
| Fluoroquinolones | 1 | 2017 | 235 | 0.60 | Why? |
| Diagnostic Errors | 1 | 2021 | 865 | 0.55 | Why? |
| Ebolavirus | 2 | 2018 | 834 | 0.54 | Why? |
| Compassionate Use Trials | 1 | 2018 | 632 | 0.53 | Why? |
| Helminthiasis | 3 | 2018 | 78 | 0.49 | Why? |
| Antitubercular Agents | 2 | 2018 | 775 | 0.45 | Why? |
| Epidemics | 3 | 2018 | 6407 | 0.39 | Why? |
| Artemisinins | 4 | 2018 | 238 | 0.39 | Why? |
| Clinical Trials as Topic | 4 | 2018 | 7330 | 0.38 | Why? |
| Drug Approval | 1 | 2018 | 1325 | 0.38 | Why? |
| Public Health Practice | 1 | 2017 | 945 | 0.38 | Why? |
| Phlebotomus | 2 | 2018 | 11 | 0.37 | Why? |
| Zika Virus Infection | 2 | 2018 | 1920 | 0.35 | Why? |
| Diagnostic Tests, Routine | 1 | 2018 | 2643 | 0.33 | Why? |
| Tuberculosis, Pulmonary | 1 | 2017 | 1171 | 0.32 | Why? |
| Population Surveillance | 4 | 2018 | 4967 | 0.32 | Why? |
| Insecticides | 2 | 2018 | 178 | 0.31 | Why? |
| Insect Vectors | 2 | 2018 | 227 | 0.30 | Why? |
| Research Design | 3 | 2018 | 5830 | 0.29 | Why? |
| Soil | 3 | 2018 | 137 | 0.25 | Why? |
| Biomedical Research | 3 | 2019 | 5270 | 0.24 | Why? |
| Tuberculosis | 1 | 2018 | 2895 | 0.23 | Why? |
| Dengue | 3 | 2018 | 1565 | 0.22 | Why? |
| Malaria, Falciparum | 2 | 2018 | 377 | 0.21 | Why? |
| Aedes | 3 | 2018 | 380 | 0.21 | Why? |
| Isoniazid | 2 | 2018 | 105 | 0.21 | Why? |
| Databases, Factual | 3 | 2021 | 6248 | 0.20 | Why? |
| Africa, Western | 2 | 2018 | 363 | 0.20 | Why? |
| Onchocerca | 1 | 2018 | 3 | 0.20 | Why? |
| Armenia | 1 | 2018 | 89 | 0.19 | Why? |
| Filaricides | 1 | 2018 | 41 | 0.19 | Why? |
| Antimalarials | 4 | 2018 | 2505 | 0.19 | Why? |
| Mebendazole | 1 | 2018 | 6 | 0.19 | Why? |
| Nifurtimox | 1 | 2018 | 1 | 0.19 | Why? |
| Eflornithine | 1 | 2018 | 3 | 0.19 | Why? |
| Trypanosoma brucei gambiense | 1 | 2018 | 23 | 0.19 | Why? |
| Schistosomiasis haematobia | 1 | 2019 | 45 | 0.18 | Why? |
| Albendazole | 1 | 2018 | 32 | 0.18 | Why? |
| Trypanocidal Agents | 1 | 2018 | 19 | 0.18 | Why? |
| Rifampin | 2 | 2018 | 276 | 0.18 | Why? |
| Taeniasis | 1 | 2017 | 9 | 0.18 | Why? |
| Insect Control | 1 | 2017 | 17 | 0.18 | Why? |
| Trypanosomiasis, African | 1 | 2018 | 31 | 0.18 | Why? |
| Plasmodium falciparum | 2 | 2017 | 337 | 0.18 | Why? |
| Ethambutol | 1 | 2017 | 34 | 0.18 | Why? |
| Taenia solium | 1 | 2017 | 26 | 0.18 | Why? |
| Capital Financing | 1 | 2017 | 35 | 0.18 | Why? |
| Leishmaniasis Vaccines | 1 | 2017 | 3 | 0.17 | Why? |
| Helminths | 1 | 2018 | 60 | 0.17 | Why? |
| Insecticide-Treated Bednets | 1 | 2017 | 77 | 0.17 | Why? |
| Intestinal Diseases, Parasitic | 1 | 2017 | 34 | 0.17 | Why? |
| Humans | 50 | 2022 | 930598 | 0.17 | Why? |
| Pyrazinamide | 1 | 2017 | 38 | 0.17 | Why? |
| Cysticercosis | 1 | 2017 | 32 | 0.17 | Why? |
| Leishmania | 1 | 2017 | 28 | 0.17 | Why? |
| Quality of Life | 1 | 2018 | 9820 | 0.16 | Why? |
| Biopsy, Fine-Needle | 1 | 2018 | 274 | 0.16 | Why? |
| Neurocysticercosis | 1 | 2017 | 51 | 0.16 | Why? |
| Strongyloides stercoralis | 1 | 2017 | 70 | 0.16 | Why? |
| Epidemiological Monitoring | 3 | 2018 | 3493 | 0.16 | Why? |
| Publication Bias | 1 | 2018 | 241 | 0.16 | Why? |
| Strongyloidiasis | 1 | 2017 | 80 | 0.16 | Why? |
| Consumer Advocacy | 1 | 2017 | 62 | 0.16 | Why? |
| Clinical Deterioration | 1 | 2021 | 473 | 0.16 | Why? |
| Biological Assay | 1 | 2018 | 367 | 0.15 | Why? |
| Public-Private Sector Partnerships | 1 | 2018 | 259 | 0.15 | Why? |
| Policy | 2 | 2021 | 1372 | 0.15 | Why? |
| Georgia | 1 | 2018 | 955 | 0.15 | Why? |
| Geography, Medical | 1 | 2018 | 537 | 0.14 | Why? |
| Disease Outbreaks | 5 | 2019 | 27595 | 0.14 | Why? |
| World Health Organization | 5 | 2021 | 4213 | 0.14 | Why? |
| Clinical Trials, Phase II as Topic | 1 | 2018 | 801 | 0.14 | Why? |
| Education | 1 | 2019 | 434 | 0.14 | Why? |
| Arylamine N-Acetyltransferase | 1 | 2012 | 15 | 0.13 | Why? |
| RNA, Small Interfering | 1 | 2018 | 817 | 0.13 | Why? |
| Clinical Protocols | 2 | 2021 | 2734 | 0.12 | Why? |
| India | 4 | 2018 | 11875 | 0.12 | Why? |
| Disease Notification | 1 | 2018 | 639 | 0.12 | Why? |
| Tuberculosis, Multidrug-Resistant | 1 | 2018 | 433 | 0.12 | Why? |
| Endemic Diseases | 1 | 2017 | 480 | 0.12 | Why? |
| Animals | 13 | 2019 | 78931 | 0.12 | Why? |
| Information Dissemination | 2 | 2018 | 2986 | 0.12 | Why? |
| Interviews as Topic | 2 | 2018 | 1952 | 0.12 | Why? |
| Cytochrome P-450 Enzyme System | 1 | 2012 | 144 | 0.12 | Why? |
| Body Temperature | 1 | 2017 | 875 | 0.11 | Why? |
| Sensitivity and Specificity | 3 | 2021 | 22971 | 0.11 | Why? |
| Bangladesh | 1 | 2017 | 1620 | 0.11 | Why? |
| Aftercare | 1 | 2021 | 1637 | 0.11 | Why? |
| United States Food and Drug Administration | 1 | 2018 | 1276 | 0.11 | Why? |
| Amodiaquine | 1 | 2010 | 57 | 0.11 | Why? |
| Chemokines | 1 | 2017 | 1095 | 0.11 | Why? |
| Health Planning | 1 | 2018 | 607 | 0.10 | Why? |
| Headache | 1 | 2021 | 2257 | 0.10 | Why? |
| Income | 1 | 2019 | 1564 | 0.10 | Why? |
| Emigrants and Immigrants | 1 | 2019 | 888 | 0.10 | Why? |
| Hospitalization | 4 | 2021 | 54280 | 0.10 | Why? |
| Zika Virus | 2 | 2018 | 1924 | 0.09 | Why? |
| Drug Industry | 1 | 2017 | 689 | 0.09 | Why? |
| Lymphopenia | 1 | 2021 | 2669 | 0.09 | Why? |
| Communicable Disease Control | 2 | 2018 | 29620 | 0.09 | Why? |
| Combined Modality Therapy | 1 | 2018 | 3395 | 0.09 | Why? |
| Delayed Diagnosis | 1 | 2018 | 1529 | 0.09 | Why? |
| Female | 20 | 2022 | 380317 | 0.09 | Why? |
| Ivermectin | 1 | 2018 | 973 | 0.09 | Why? |
| Rural Population | 2 | 2018 | 2408 | 0.09 | Why? |
| Heart Rate | 1 | 2017 | 1527 | 0.09 | Why? |
| Male | 18 | 2021 | 367725 | 0.09 | Why? |
| Bolivia | 2 | 2018 | 187 | 0.09 | Why? |
| Swine Diseases | 1 | 2017 | 1219 | 0.09 | Why? |
| Disease Reservoirs | 1 | 2017 | 1672 | 0.08 | Why? |
| Cough | 1 | 2021 | 4891 | 0.08 | Why? |
| Antigens, Viral | 2 | 2021 | 6298 | 0.08 | Why? |
| Clinical Decision-Making | 1 | 2021 | 3755 | 0.08 | Why? |
| Endothelial Cells | 1 | 2017 | 2048 | 0.08 | Why? |
| Qualitative Research | 1 | 2018 | 4337 | 0.08 | Why? |
| Age Factors | 4 | 2021 | 21039 | 0.07 | Why? |
| Internationality | 1 | 2018 | 3297 | 0.07 | Why? |
| Chemoprevention | 2 | 2021 | 585 | 0.07 | Why? |
| Hospital Mortality | 4 | 2021 | 22087 | 0.07 | Why? |
| Erythrocytes | 2 | 2017 | 617 | 0.07 | Why? |
| C-Reactive Protein | 1 | 2021 | 7972 | 0.07 | Why? |
| Sex Factors | 2 | 2018 | 11014 | 0.07 | Why? |
| Fever | 1 | 2021 | 7795 | 0.07 | Why? |
| Symptom Assessment | 1 | 2018 | 4967 | 0.07 | Why? |
| Erythrocyte Aging | 1 | 2003 | 13 | 0.07 | Why? |
| Aged | 11 | 2022 | 215776 | 0.06 | Why? |
| Malaria | 1 | 2012 | 1097 | 0.06 | Why? |
| Drug Discovery | 1 | 2017 | 3092 | 0.06 | Why? |
| Adolescent | 8 | 2022 | 86841 | 0.06 | Why? |
| Pharmaceutical Preparations | 1 | 2017 | 1897 | 0.06 | Why? |
| Models, Theoretical | 2 | 2018 | 6659 | 0.06 | Why? |
| Disease Progression | 1 | 2021 | 13580 | 0.06 | Why? |
| Lipid Peroxidation | 2 | 2017 | 114 | 0.06 | Why? |
| Betacoronavirus | 3 | 2020 | 204454 | 0.06 | Why? |
| Time-to-Treatment | 1 | 2018 | 5883 | 0.06 | Why? |
| Child, Preschool | 4 | 2020 | 36283 | 0.06 | Why? |
| Treatment Outcome | 5 | 2021 | 51732 | 0.06 | Why? |
| Mass Screening | 1 | 2021 | 8005 | 0.05 | Why? |
| Child | 6 | 2022 | 70012 | 0.05 | Why? |
| United Kingdom | 4 | 2021 | 18046 | 0.05 | Why? |
| Systemic Inflammatory Response Syndrome | 1 | 2020 | 6653 | 0.05 | Why? |
| Schistosoma haematobium | 1 | 2019 | 35 | 0.05 | Why? |
| Dominican Republic | 1 | 2018 | 57 | 0.05 | Why? |
| Mice, Inbred NOD | 1 | 2018 | 134 | 0.05 | Why? |
| Quinine | 1 | 2018 | 56 | 0.05 | Why? |
| Young Adult | 6 | 2020 | 93724 | 0.05 | Why? |
| Mice, SCID | 1 | 2018 | 225 | 0.05 | Why? |
| Pandemics | 6 | 2021 | 389249 | 0.05 | Why? |
| Hydroxyeicosatetraenoic Acids | 1 | 2017 | 5 | 0.04 | Why? |
| Adult | 8 | 2021 | 244371 | 0.04 | Why? |
| Hemeproteins | 1 | 2017 | 8 | 0.04 | Why? |
| Tropical Medicine | 1 | 2021 | 237 | 0.04 | Why? |
| Middle Aged | 8 | 2021 | 270681 | 0.04 | Why? |
| Child, Hospitalized | 1 | 2022 | 556 | 0.04 | Why? |
| Nitroimidazoles | 1 | 2018 | 69 | 0.04 | Why? |
| Oxazoles | 1 | 2018 | 75 | 0.04 | Why? |
| Sierra Leone | 1 | 2018 | 267 | 0.04 | Why? |
| Pneumonia, Viral | 3 | 2020 | 243684 | 0.04 | Why? |
| Epidemiologic Research Design | 1 | 2019 | 166 | 0.04 | Why? |
| Follow-Up Studies | 3 | 2022 | 17020 | 0.04 | Why? |
| Coronavirus Infections | 3 | 2020 | 253789 | 0.04 | Why? |
| Risk Assessment | 2 | 2020 | 25439 | 0.04 | Why? |
| Health Policy | 1 | 2017 | 6242 | 0.04 | Why? |
| Travel Medicine | 1 | 2021 | 335 | 0.04 | Why? |
| Russia | 1 | 2021 | 989 | 0.04 | Why? |
| Comorbidity | 1 | 2021 | 34796 | 0.04 | Why? |
| Organizations, Nonprofit | 1 | 2017 | 87 | 0.04 | Why? |
| Competitive Behavior | 1 | 2017 | 111 | 0.04 | Why? |
| Drug Resistance | 1 | 2018 | 395 | 0.04 | Why? |
| Risk Factors | 3 | 2022 | 71621 | 0.04 | Why? |
| False Positive Reactions | 1 | 2021 | 1338 | 0.04 | Why? |
| Mosquito Vectors | 1 | 2018 | 351 | 0.04 | Why? |
| Predictive Value of Tests | 2 | 2021 | 9537 | 0.04 | Why? |
| Vaccination | 1 | 2021 | 19050 | 0.04 | Why? |
| Infectious Disease Medicine | 1 | 2018 | 311 | 0.04 | Why? |
| Stress, Psychological | 1 | 2018 | 10231 | 0.03 | Why? |
| Health Plan Implementation | 1 | 2019 | 571 | 0.03 | Why? |
| Government Programs | 1 | 2018 | 512 | 0.03 | Why? |
| Developing Countries | 2 | 2021 | 4283 | 0.03 | Why? |
| Nepal | 1 | 2018 | 1004 | 0.03 | Why? |
| Uganda | 1 | 2018 | 1057 | 0.03 | Why? |
| False Negative Reactions | 1 | 2021 | 1785 | 0.03 | Why? |
| Global Health | 1 | 2018 | 13911 | 0.03 | Why? |
| Africa South of the Sahara | 1 | 2019 | 1335 | 0.03 | Why? |
| Surveys and Questionnaires | 1 | 2021 | 43792 | 0.03 | Why? |
| Endothelium | 1 | 2017 | 460 | 0.03 | Why? |
| Malaysia | 1 | 2018 | 1116 | 0.03 | Why? |
| Mefloquine | 1 | 2012 | 39 | 0.03 | Why? |
| Isoenzymes | 1 | 2012 | 127 | 0.03 | Why? |
| Respiratory Tract Diseases | 1 | 2021 | 1061 | 0.03 | Why? |
| Cambodia | 1 | 2012 | 190 | 0.03 | Why? |
| Ethanolamines | 1 | 2012 | 71 | 0.03 | Why? |
| Fluorenes | 1 | 2012 | 101 | 0.03 | Why? |
| Tanzania | 1 | 2012 | 294 | 0.03 | Why? |
| Prospective Studies | 3 | 2022 | 43301 | 0.03 | Why? |
| Cohort Studies | 3 | 2020 | 36005 | 0.03 | Why? |
| Prevalence | 3 | 2019 | 25773 | 0.03 | Why? |
| Infant | 3 | 2020 | 30274 | 0.03 | Why? |
| Drug Combinations | 2 | 2012 | 3852 | 0.03 | Why? |
| United States | 1 | 2018 | 46150 | 0.03 | Why? |
| Fibrinogen | 1 | 2017 | 1048 | 0.03 | Why? |
| Pharmacogenetics | 1 | 2012 | 222 | 0.03 | Why? |
| Dengue Virus | 1 | 2018 | 910 | 0.03 | Why? |
| Informed Consent | 1 | 2018 | 890 | 0.03 | Why? |
| Powders | 1 | 2010 | 121 | 0.03 | Why? |
| Meta-Analysis as Topic | 1 | 2017 | 1289 | 0.03 | Why? |
| Tablets | 1 | 2010 | 219 | 0.03 | Why? |
| Drug Stability | 1 | 2010 | 236 | 0.02 | Why? |
| Safety | 1 | 2018 | 1583 | 0.02 | Why? |
| Program Evaluation | 1 | 2018 | 1929 | 0.02 | Why? |
| Solvents | 1 | 2010 | 139 | 0.02 | Why? |
| Mexico | 1 | 2018 | 2787 | 0.02 | Why? |
| Solubility | 1 | 2010 | 382 | 0.02 | Why? |
| Chemistry, Pharmaceutical | 1 | 2010 | 152 | 0.02 | Why? |
| Up-Regulation | 1 | 2017 | 2249 | 0.02 | Why? |
| Mycobacterium tuberculosis | 1 | 2018 | 1164 | 0.02 | Why? |
| Quinolines | 1 | 2012 | 403 | 0.02 | Why? |
| Data Collection | 1 | 2018 | 1769 | 0.02 | Why? |
| Swine | 1 | 2017 | 3352 | 0.02 | Why? |
| Drug Compounding | 1 | 2010 | 386 | 0.02 | Why? |
| ROC Curve | 1 | 2020 | 6024 | 0.02 | Why? |
| Cost-Benefit Analysis | 1 | 2018 | 2259 | 0.02 | Why? |
| Gene Frequency | 1 | 2012 | 1210 | 0.02 | Why? |
| Incidence | 2 | 2021 | 25622 | 0.02 | Why? |
| Pilot Projects | 1 | 2019 | 5182 | 0.02 | Why? |
| Age Distribution | 1 | 2017 | 3567 | 0.02 | Why? |
| Monitoring, Physiologic | 1 | 2018 | 1956 | 0.02 | Why? |
| Critical Care | 2 | 2021 | 14081 | 0.02 | Why? |
| Alleles | 1 | 2012 | 1557 | 0.02 | Why? |
| Hydrogen-Ion Concentration | 1 | 2010 | 993 | 0.02 | Why? |
| Patient Care Team | 1 | 2021 | 3556 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2017 | 5440 | 0.02 | Why? |
| Aged, 80 and over | 3 | 2021 | 88759 | 0.02 | Why? |
| Software | 1 | 2018 | 2501 | 0.02 | Why? |
| Curriculum | 1 | 2019 | 3083 | 0.02 | Why? |
| Survival Rate | 1 | 2020 | 9206 | 0.02 | Why? |
| Logistic Models | 1 | 2021 | 9089 | 0.02 | Why? |
| Odds Ratio | 1 | 2017 | 5861 | 0.02 | Why? |
| Water | 1 | 2010 | 765 | 0.02 | Why? |
| Respiration, Artificial | 2 | 2021 | 22116 | 0.02 | Why? |
| Ethanol | 1 | 2010 | 533 | 0.02 | Why? |
| Base Sequence | 1 | 2012 | 3581 | 0.02 | Why? |
| Gene Expression Regulation | 1 | 2017 | 4020 | 0.02 | Why? |
| Thiobarbituric Acid Reactive Substances | 1 | 2003 | 20 | 0.02 | Why? |
| Research | 1 | 2017 | 2115 | 0.02 | Why? |
| Reproducibility of Results | 1 | 2021 | 11304 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2018 | 7268 | 0.02 | Why? |
| Humidity | 1 | 2010 | 944 | 0.02 | Why? |
| Patient Admission | 1 | 2021 | 5250 | 0.02 | Why? |
| Sequence Analysis, DNA | 1 | 2012 | 2830 | 0.02 | Why? |
| Bystander Effect | 1 | 2003 | 68 | 0.02 | Why? |
| Erythrocyte Membrane | 1 | 2003 | 56 | 0.02 | Why? |
| Zoonoses | 1 | 2017 | 3034 | 0.02 | Why? |
| Membrane Lipids | 1 | 2003 | 91 | 0.02 | Why? |
| Fatty Acids, Unsaturated | 1 | 2003 | 70 | 0.02 | Why? |
| Patient Safety | 1 | 2018 | 4885 | 0.02 | Why? |
| Coculture Techniques | 1 | 2003 | 258 | 0.01 | Why? |
| Hot Temperature | 1 | 2010 | 1299 | 0.01 | Why? |
| Nervous System Diseases | 1 | 2021 | 4092 | 0.01 | Why? |
| Public Health | 2 | 2018 | 16359 | 0.01 | Why? |
| Protozoan Proteins | 1 | 2003 | 205 | 0.01 | Why? |
| Kinetics | 1 | 2010 | 3238 | 0.01 | Why? |
| Seroepidemiologic Studies | 1 | 2017 | 10017 | 0.01 | Why? |
| Fatty Acids | 1 | 2003 | 238 | 0.01 | Why? |
| Hospitals | 1 | 2021 | 11793 | 0.01 | Why? |
| Cell Line | 1 | 2017 | 12040 | 0.01 | Why? |
| Phospholipids | 1 | 2003 | 202 | 0.01 | Why? |
| Cross-Sectional Studies | 2 | 2018 | 53120 | 0.01 | Why? |
| Feasibility Studies | 1 | 2010 | 3467 | 0.01 | Why? |
| Brazil | 1 | 2018 | 12582 | 0.01 | Why? |
| Models, Statistical | 1 | 2018 | 5312 | 0.01 | Why? |
| Patient Acceptance of Health Care | 1 | 2018 | 5002 | 0.01 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2012 | 3607 | 0.01 | Why? |
| Infant, Newborn | 1 | 2020 | 23105 | 0.01 | Why? |
| Mice | 1 | 2018 | 21357 | 0.01 | Why? |
| Cholesterol | 1 | 2003 | 660 | 0.01 | Why? |
| Prognosis | 1 | 2021 | 32490 | 0.01 | Why? |
| Retrospective Studies | 2 | 2019 | 105322 | 0.01 | Why? |
| Cardiovascular Diseases | 1 | 2021 | 11497 | 0.01 | Why? |
| Italy | 1 | 2019 | 38444 | 0.01 | Why? |
| Intensive Care Units | 1 | 2021 | 29594 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2021 | 48226 | 0.01 | Why? |
| Membrane Proteins | 1 | 2003 | 1733 | 0.01 | Why? |
| Oxidative Stress | 1 | 2003 | 2050 | 0.01 | Why? |
| Antiviral Agents | 1 | 2021 | 41703 | 0.01 | Why? |